全文获取类型
收费全文 | 101154篇 |
免费 | 9211篇 |
国内免费 | 4290篇 |
专业分类
耳鼻咽喉 | 1679篇 |
儿科学 | 2462篇 |
妇产科学 | 1388篇 |
基础医学 | 10670篇 |
口腔科学 | 8116篇 |
临床医学 | 9365篇 |
内科学 | 8962篇 |
皮肤病学 | 990篇 |
神经病学 | 3231篇 |
特种医学 | 5356篇 |
外国民族医学 | 68篇 |
外科学 | 16941篇 |
综合类 | 16975篇 |
预防医学 | 2914篇 |
眼科学 | 754篇 |
药学 | 6370篇 |
63篇 | |
中国医学 | 3195篇 |
肿瘤学 | 15156篇 |
出版年
2024年 | 86篇 |
2023年 | 1494篇 |
2022年 | 2222篇 |
2021年 | 3857篇 |
2020年 | 3802篇 |
2019年 | 3198篇 |
2018年 | 2921篇 |
2017年 | 3504篇 |
2016年 | 3609篇 |
2015年 | 3805篇 |
2014年 | 6317篇 |
2013年 | 7082篇 |
2012年 | 5671篇 |
2011年 | 6431篇 |
2010年 | 5372篇 |
2009年 | 5202篇 |
2008年 | 5175篇 |
2007年 | 5447篇 |
2006年 | 4914篇 |
2005年 | 4498篇 |
2004年 | 3926篇 |
2003年 | 3387篇 |
2002年 | 3018篇 |
2001年 | 2685篇 |
2000年 | 2191篇 |
1999年 | 1922篇 |
1998年 | 1570篇 |
1997年 | 1452篇 |
1996年 | 1274篇 |
1995年 | 1173篇 |
1994年 | 1062篇 |
1993年 | 812篇 |
1992年 | 728篇 |
1991年 | 604篇 |
1990年 | 486篇 |
1989年 | 459篇 |
1988年 | 413篇 |
1987年 | 346篇 |
1986年 | 290篇 |
1985年 | 361篇 |
1984年 | 304篇 |
1983年 | 227篇 |
1982年 | 278篇 |
1981年 | 227篇 |
1980年 | 173篇 |
1979年 | 178篇 |
1978年 | 158篇 |
1977年 | 105篇 |
1976年 | 103篇 |
1975年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
2.
3.
4.
外泌体是一类直径为30~100 nm的圆盘囊泡,其内包含许多组分,诸如复杂RNA和蛋白质等,主要参与细胞间的信号转导。肿瘤相关巨噬细胞(tumor-associated macrophages,TAMs)是肿瘤微环境中普遍存在的巨噬细胞,通过对肿瘤生长、免疫逃逸、侵袭和转移、耐药性等多方面的作用影响肿瘤进程。外泌体在肿瘤相关巨噬细胞的招募、极化及抗肿瘤免疫调控等方面发挥着重要的调节功能。同时,TAMs以外泌体为媒介作用于肿瘤细胞,从而构成了外泌体、TAMs与肿瘤细胞之间相互作用的调控通路。综上所述,本文旨在阐明肿瘤细胞与TAMs之间,以外泌体为“桥梁”相互影响的潜在机制,以及靶向肿瘤细胞和TAMs来源的外泌体在恶性肿瘤治疗中的展望。 相似文献
5.
6.
7.
8.
目的 通过研究明确苗药五藤膏外敷缓解胶原诱导性关节炎(CIA)大鼠关节局部炎症和骨破坏的机制,证实苗医外治就近驱邪的作用。方法 将70只Wistar大鼠随机分为空白组、模型组、苗药五藤膏高、中、低剂量组、扶他林组及IL-17阻断组,每组10只。除空白组外,其余6组均构建CIA模型,并给予相应的外敷治疗。观察大鼠一般情况,HE染色进行病理学分析,TRAP染色检测OC生成,ELISA检测各炎症因子的含量,RT-PCR和WB分别检测RANKL的基因及蛋白表达。结果 苗药五藤膏能改善CIA大鼠破骨细胞浸润及关节病理性结构,并降低RANKL蛋白、基因表达以及TNF-α、IL-1、IL-6、IL-17含量。结论 苗药五藤膏外敷剂对CIA大鼠的治疗机制可能与降低致炎因子的分泌,抑制RANKL及OC的表达相关。 相似文献
9.
BackgroundCentrally located pancreatic lesions are often treated with extended pancreaticoduodenectomy or distal pancreatectomy resulting in loss of healthy parenchyma and a high risk of diabetes and exocrine insufficiency. Robotic central pancreatectomy (RCP) is a parenchyma sparring alternative that has been shown safe and feasible [[1], [2]].MethodsIn this article, we describe our operative technique and the perioperative outcomes of a series of RCP for low-grade or benign pancreatic tumors.ResultsSix patients (5 female and 1 man) with a median age of 51.5 (44–68) years underwent a RCP for 2 serous cystadenomas, 2 mucinous cystic tumors, 1 neuroendocrine tumor, and 1 autoimmune pancreatitis. There were no conversions, intraoperative complications, or perioperative transfusions. Median operative time and was 240 (230–291) minutes and median blood loss was 100 (100–400) ml. The median hospital stay was 8 (5–27) days. There were no mortalities, reoperations, or readmissions. One patient developed a grade B pancreatic fistula which was successfully managed conservatively. All resections had free margins and the median tumor size was 2.5 (1.5–3.5) cm. After a mean follow-up of 46 months, no patients presented new-onset diabetes or exocrine insufficiency.ConclusionsRCP represents the least invasive option for both the patient and the pancreatic parenchyma. With a standardized technique, RCP results in low postoperative morbidity and excellent long-term pancreatic function. Although our results are excellent, POPF still represents the main complication of central pancreatectomy with an incidence ranging from 0 to 80% depending on multiple factors such as the surgeon, technique, and pancreatic texture. 相似文献
10.
Xi Tian Yue Wang Wenhao Xu Haidan Tang Shuxuan Zhu Aihetaimujiang Anwaier Wangrui Liu Wenfeng Wang Wenkai Zhu Jiaqi Su Yuanyuan Qu Hailiang Zhang Dingwei Ye 《International journal of cancer. Journal international du cancer》2023,152(1):66-78
In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with everolimus or nivolumab) were downloaded from public databases. Proteomic profiles of 232 ccRCC samples were obtained from Fudan University Shanghai Cancer Center (FUSCC). Biological changes, tumor microenvironment and prognostic differences were explored between samples with various glycolysis characteristics. There were significant differences in CD8+ effector T cells, epithelial-to-mesenchymal transition and pan-fibroblast TGFb between the Low and High glyScore groups. The tumor mutation burden of the Low glyScore group was lower than that of the High glyScore group. And higher glyScore was significantly associated with worse overall survival (OS) in 768 ccRCC patients (P < .0001). External validation in FUSCC cohort also indicated that glyScore was of strong ability for predicting OS (P < .05). GlyScore may serve as a biomarker for predicting everolimus response in ccRCC patients due to its significant associations with progression-free survival (PFS). And glyScore may also predict overall survival in patients treated with nivolumab. We calculated the glyScore in ccRCC and the defined glyScore was of strong ability for predicting OS. In addition, glyScore may also serve as a biomarker for predicting PFS in patients treated with everolimus and could predict OS in patients treated with nivolumab. 相似文献